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CKD may attenuate efﬁcacy of DES.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Inﬂammation, Long-term clinical outcomes
TCT-606
Early DES and BMS healing proﬁle assessed by OCT and proteomics in a pig
model
Wojciech Wojakowski,1 Gonca Suna,2 Jonathan M. Hill,3
Javier Barallobre-Barreiro,2 Pawel Gasior,4 Xiaoke Yin,2
Tomasz Roleder,5 Krzysztof P. Milewski,6 Piotr P. Buszman,7
Buszman E. Pawel,8 Manuel Mayr9
1Medical University of Silesia, Katowice, Poland; 2Kings College
London, London, United Kingdom; 3King’s College Hospital, King’s
Health Partners, London, United Kingdom; 4Medical University of
Silesia, Silesian Center for Heart Diseases, Zabrze, Poland; 5Medical
University of Silesia, Katowice, Poland, Katowice, Poland; 6American
Heart of Poland, Katowice, Poland; 7American Heart of Poland,
Katowice and Silesian Center for Heart Diseases, Zabrze Poland,
Katowice, Poland; 8American Heart of Poland, Ustron, Poland; 9Kings
College London, London, United Kingdom
BACKGROUND The strut coverage in OCT is used as a surrogate
marker of chronic stent healing, however less data is available
regarding the acute healing response in the ﬁrst week.
METHODS There were 13 BMS and 15 DES implanted into the coronary
arteries in an overstretch model. OCT follow-up was performed at 1, 3, 7,
14, and 28 days post implantation and assessed strut apposition, coverage
and neoinitmal volume per 1 mm of stent (CAAS intravascular, Pie Medi-
cal). A proteomic approach was used to measure changes in proteins
expression in the arterial neointima over time following implantation of
drug-eluting (DES, Xience Pro, Abbott, USA) and same metallic platform
bare-metal stents (BMS, MLVision, Abbott, USA) compared to balloon an-
gioplasty in porcine coronary arteries.
RESULTS In the early period after implantation a higher neointimal
volume per 1 mm for BMS (0.240.028mm3 vs. 0.250.024mm3;
p¼0.025) without differences between BMS and DES in the stent struts
malapposition (6.842.63% vs. 8.042.35%; p¼0.75) and in stent strut
coverage (45.504.94% vs. 36.734.41%; p¼0.25) was found. At 28
days post implantation the difference in in-stent neoinitmal volume
per 1mm (0.700.13 vs. 0.680.02; p¼0.89), struts coverage
(94.8442.89 vs. 98.9310.51 p¼0.778) and number of malapposed
struts (0.8660.52 vs. 0.4070.40 p¼0.238) were similar for BMS and
DES. Animals were sacriﬁced at each of these time-points and their
coronary arteries were retrieved with subsequent separate analysis of
the vascular media and neointima (for time-point 28). A total of 145
ECM and ECM-associated proteins were identiﬁed by mass spec-
trometry. A comparison of the media versus neointima revealed an
increase of collagens and regulatory proteins, such as small leucine
rich proteins in the media, while basement membrane proteins were
predominantly found in the neointima. Only by day 28, the neointima
in DES compared to BMS showed increased expression of proteins
involved in the regulation of calciﬁcation.
CONCLUSIONS Early healing events in ﬁrst week after stent implan-
tation involve less neointimal volume in DES and initially similarproteomic proﬁles for DES and BMS. After 28 days there are differ-
ences in extracellular matrix-related protens between DES and BMS. It
suggest the high biocompatibility of permanent ﬂuorinated polymer
coated DES in the acute phase after implantation.
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BACKGROUND Late stent failures (late stent thrombosis, late catch-
up, and accelerated neoatherosclerosis) were reported in mono-
therapy drug eluting stents (DES). The beneﬁts of the new “dual”
therapy endothelial-progenitor-cell capturing sirolimus-eluting
COMBO stent (OrbusNeich, FL, US) were analyzed.
METHODS Four longitudinal sequential OCTs in each patient were
obtained in this prospective, single center study; at baseline (for best
stent optimization); at early FUs from 2-5M (4 monthly groups in
1:2:2:1 ratio for % strut coverage); at 9M (for neointima metrics), and at
24M (for neointimal changes). Clinical event adjudication & OCT an-
alyses were performed by CRF core laboratory.
RESULTS 61 patients (33% DM and 74 lesions) received 88 COMBO
stents. All 61 patients completed 9M OCT FU but 17 asymptomatic
cases refused 24M OCT (FU rate 68.3%). Median strut coverage
increased from 77.1, 92.5, 92.7, 94.9, 99.5, to 99.2% from 2M, 3M, 4M,
5M, 9M, to 24M, respectively. No late stent thrombosis was recorded
at 36M (clinical FU rate 98.3%) and MACE rate 3.28%. Regarding late
catch-up, rather, signiﬁcant neointima “regression” was documented
from 9M to 24M; in-stent % neointimal volume (%) 17$8 (12$2-21$2) vs
15$7 (11$2-19$4), p¼0.011. Extra-stent-lumen area (Figure 2) was
recorded in 31$1% (23/74) of lesions during ﬁrst OCT (2 to 5M); this
disappeared signiﬁcantly by 9M, representing rapid vessel healing.
Progressively increase in homogeneous neointima (conversion from
heterogeneous & layered neointima) with reduction in peri-strut-low-
density area was observed (Figure 2), representing neointimal matu-
ration without accelerated neoatherosclerosis.1st OCT Follow-up 2nd OCT FU 3rd OCT FU P-value2 months 3 months 4 months 5 monthsP-value 2 vs
5M 9 months 24 months 9 vs. 24MTotal number of
lesions
analyzedn ¼ 12 n ¼ 24 n ¼ 25 n ¼ 13 NA n ¼ 74 n ¼ 51 NAMedian stent
length
analyzed
(mm)23$5 (21$7-
36$4)23$5 (18$8-
26$6)23$2 (18$8-
24$6)19$6 (19$0-
23$4)0$49 22$9 (18$2-
25$4)22$6 (17$8-
25$0)0$67Total number of
frames
analyzedn ¼ 347 n ¼ 627 n ¼ 642 n ¼ 300 NA n ¼ 1884 n ¼ 1279 NATotal number of
struts
analyzedn ¼ 3430 n ¼ 6360 n ¼ 6505 n ¼ 2946 NA n ¼ 18904 n ¼ 12822 NAStrut coverage percentage as deﬁned by 6 categoriesCovered (DþEþF)
(%)77$1 (67$1-
84$7)92$5 (81$9-
94$3)92$7 (86$8-
95$3)94$9 (89$6-
97$6)0$046 99$5 (97$8-
99$9)99$2 (98$6-
99$8)0$62Uncovered
(AþBþC) (%)
22$9 (15$3-
32$9)7$5 (5$7-18$1) 7$4 (4$7-13$2) 5$1 (2$4-10$5) 0$045 0$5 (0$1-2$2) 0$8 (0$2-1$4) 0$60Strut level and frame (cross-section) level OCT analysesMalapposed struts
(%)0$1 (0$1-0$7) 0$4 (0$3-0$7) 0$5 (0$1-0$9) 0$4 (0$1-0$6) 0$64 0$1 (0$1-0$5) 1$3 (1$3-1$3) NANeointimal
thickness
(mm)0$04 (0$00-
0$06)0$04 (0$03-
0$07)0$04 (0$03-
0$07)0$04 (0$03-
0$08)0$49 0$14 (0$08-
0$21)0$12 (0$07-
0$19)<0$001Neointimal area
(NIA) (mm2)0.56 (0.32-
0.63)0.47 (0.33-
0.59)0.55 (0.35-
0.75)0.61 (0.41-
0.90)0.44 1$34 (1$02-
1$65)1$16 (0$92-
1$52)0.001Neointimal volume
(NIV) (mm3)13$6 (9$2-
15$0)10$2 (6$7-
15$17)13$47 (6$0-
18$57)13$7 (10$0-
17$0)0$95 29$9 (22$1-
43$2)26$2 (19$6-
35$8)0$003Percentage NIV
(%)6$8 (3$3-8$4) 6$0 (4$2-8$0) 6$7 (5$2-7$9) 7$5 (6$3-8$9) 0$41 17$8 (12$2-
21$2)15$7 (11$2-
19$4)0$011
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ment of late stent failure was observed in this new dual therapy
COMBO DES up to 3 years.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Endothelial Progenitor cell capture stent, Late Stent
Failure, Optical coherence tomography
TCT-608
Comparison of stent design on early outcome in patients undergoing
primary percutaneous coronary intervention. Insights from large,
multicenter, registry
Piotr P. Buszman,1 Krzysztof P. Milewski,2 Marek Gierlotka,3
Włodzimierz Grocholewski,2 Aleksander Zurakowski,4 Marek Krol,2
Marek Kondys,5 Janusz Prokopczuk,6 Bogdan Gorycki,7
Buszman E. Pawel8
1American Heart of Poland, Katowice and Silesian Center for Heart
Diseases, Zabrze Poland, Katowice, Poland; 2American Heart of
Poland, Katowice, Poland; 3Medical University of Silesia, Silesian
Center for Heart Diseases, Zabrze, Poland; 4American Heart of Poland,
Chrzanow, Poland; 5American Heart of Poland, Dabrowa-Gornicza,
Poland; 6American Heart of Poland, Kedzierzyn Kozle, Poland;
7American Heart of Poland, Bielsko, Poland; 8American Heart of
Poland, Ustron, Poland
BACKGROUND In ST elevation myocardial infarction (STEMI) pa-
tients undergoing primary percutaneous coronary intervention (PCI),
treatment with a mesh-covered bare metal stents instead of con-
ventional stents could potentially improve outcomes. Currently
several clinically available drug eluting stents (DES) have similar,
dense-strut structure. Therefore we compared early outcomes of
patients revascularized with dense (dsDES) and regular structure
DES.METHODS In this multicenter, prospective, web-based registry we
enrolled consecutive patients presenting with anterior wall STEMI
treated with primary PCI and single stent implantation. Dense struc-
ture DES (dsDES) were deﬁned as stents with cell area less than 1 mm2
in the 3.0 x 18 mm stent and consisted of either Alex (Balton, Poland)
or Biomatrix (Biosensors, Switzerland). Otherwise, regular structure
DES consisted of Xience V (Abbott, USA), Resolute Integrity (Med-
tronic, USA) and Promus Element (Boston Scientiﬁc). In-hospital
temporal CK-MB mass release and ﬁnal ejection fractions were
evaluated.
RESULTS In total 1777 patients were included. Dense structure DES
were implanted in 1569 patients, whereas regular DES in 208. The
baseline group demographic and clinical characteristics were well-
balanced. The baseline (248  2699 vs. 162  2164 ng/ml; p¼0,60)
and 12 hour (681  2699 vs. 1366  7659 vs. ng/ml; p¼0,6) CKMB
release after PCI was similar between dense and regular structure
DES. At 24 (345  3300 vs. 1104  6701 ng/ml; p¼0.16) and 48
hours (38  38 vs. 986  8186 p¼0.11) there was a trend toward
lower CKMB values in the dsDES when compared to DES. The area
under curve of CKMB temporal release was not different between
dense and regular structure DES (3918  3871 vs. 4084  3948
p¼0.50.). There was also no difference in left ventricle ejection
fraction (42.6  10 vs. 41.8  11 p¼0.31) or major adverse clinical
events.
CONCLUSIONS In this large registry of patients undergoing primary
PCI, implantation of a dense structure DES was not associated with
higher level of cardioprotection as expressed by lower cardiac enzyme
release in patients undergoing primary PCI.
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BACKGROUND Primary percutaneous coronary intervention (PCI) in
ST Segment Elevation Myocardial Infarction (STEMI) is associated
with greater risk of late stent malapposition and stent thrombosis. The
aim was to assess changes in stent apposition, strut coverage, 1 year
after Resolute Integrity stent implantation in patients with STEMI
treated with primary PCI.
METHODS Seventy-four STEMI patients treated with primary PCI
were examined with optical coherence tomography (OCT) of the
stented segment within 72 hours after primary PCI and after 1 year.
RESULTS A total of 18,875 struts were analyzed post-PCI and 19,208
struts after 1 year. Acute malapposition was seen in 59 patients
(79.7%) and in 21 patients (28.4%) after 1 year. Malapposition was
resolved in 41 patients (69.5%) and late acquired in 3 patients (14.3%).
The percentage of malapposed struts was 5.8% post-PCI and 0.6%
(p<0.001) after 1 year. After 1 year, 88.7% stent struts were covered
and the median neointimal thickness was 120.0 (100 - 60) mm. The
percentage of covered struts was lower in patients with post-PCI
malapposition (84.9% vs. 95.6%, p¼0.004). Complete strut coverage
was seen in 9.5% of patients after 1 year. Thrombus was present in
90.5% post-PCI (red 208.3 quadrants, white 21.4 quadrants, and mixed
57.9 quadrants).
CONCLUSIONS Complete strut coverage was only seen in 1 out of 10
patients. Strut coverage was lower in patients with post-PCI
malapposition.
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